Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01991509 · ClinicalTrials.gov registry record · Phase 1
Safety and Bioavailability of IV and SC LBR-101
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01991509 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 36 participants.
The verdict
NCT01991509, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and blood levels of LBR-101 when administered intravenously or subcutaneously to healthy volunteers.
Interventions
- BIOLOGICAL LBR-101 IV
- BIOLOGICAL LBR-101 SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01991509
The ClinicalTrials.gov registry entry for NCT01991509 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LBR-101 IV is the first listed.
NCT01991509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01991509 about?
NCT01991509 is a clinical study titled "Safety and Bioavailability of IV and SC LBR-101". The purpose of this study is to assess the safety, tolerability and blood levels of LBR-101 when administered intravenously or subcutaneously to healthy volunteers.
What is the current status of trial NCT01991509?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-10. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01991509?
The interventions under investigation include: LBR-101 IV (BIOLOGICAL), LBR-101 SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT01991509?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.